avapro has been researched along with Albuminuria in 74 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Albuminuria: The presence of albumin in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to assess the effects of irbesartan alone and combined with amlodipine, efonidipine, or trichlormethiazide on blood pressure (BP) and urinary albumin (UA) excretion in hypertensive patients with microalbuminuria (30≤UA/creatinine (Cr) ratio [UACR] <300 mg/g Cr) and upper-normal microalbuminuria (10≤UACR<30 mg/g Cr)." | 9.27 | Effect of amlodipine, efonidipine, and trichlormethiazide on home blood pressure and upper-normal microalbuminuria assessed by casual spot urine test in essential hypertensive patients. ( Asayama, K; Hanazawa, T; Hosaka, M; Imai, Y; Inoue, R; Obara, T; Ohkubo, T; Satoh, M; Watabe, D, 2018) |
| "In a multi-center, single-arm, prospective study, we investigated the efficacy and safety of the fixed irbesartan/hydrochlorothiazide combination in Chinese patients with moderate to severe hypertension." | 9.17 | Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension. ( Dai, QY; Huang, QF; Li, Y; Ma, GS; Sheng, CS; Wang, JG, 2013) |
| " Therefore, we investigated the effects of irbesartan treatment on plasma levels of the AGEs N(ε)(1-carboxymethyl)lysine (CML) and N(ε)(1-carboxyethyl)lysine (CEL) in hypertensive patients with type 2 diabetes and microalbuminuria." | 9.15 | Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial. ( Engelen, L; Ferreira, I; Hovind, P; Parving, HH; Persson, F; Rossing, P; Schalkwijk, CG; Stehouwer, CD; Teerlink, T, 2011) |
| " After a 1-month washout period, 26 patients with type 2 diabetes, hypertension, and albuminuria (>100 mg/day) were randomly assigned to four 2-month treatment periods in random order with placebo, 300 mg aliskiren once daily, 300 mg irbesartan once daily, or the combination using identical doses." | 9.14 | Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. ( Boomsma, F; Danser, AH; Frandsen, E; Juhl, T; Parving, HH; Persson, F; Reinhard, H; Rossing, P; Schalkwijk, C; Stehouwer, CD, 2009) |
| "The Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial demonstrated that adding aliskiren, an oral direct renin inhibitor, at a dosage of 300 mg/d to the highest approved dosage of losartan and optimal antihypertensive therapy reduces albuminuria over 6 mo among patients with type 2 diabetes, hypertension, and albuminuria." | 7.75 | Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. ( Charney, A; Delea, TE; Lau, H; Munk, VC; Palmer, JL; Parving, HH; Sofrygin, O; Sullivan, SD; Sung, J, 2009) |
| "Diabetic spontaneously hypertensive rats developed albuminuria and had a reduction in both gene and protein expression of nephrin when compared with control rats." | 7.71 | Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. ( Allen, TJ; Boner, G; Bonnet, F; Cao, Z; Cooper, ME; Kawachi, H, 2001) |
| "We investigated, in individuals with type 2 diabetes, whether irbesartan lowered plasma levels of the dicarbonyls methylglyoxal, glyoxal, 3-deoxyglucosone and their derived advanced glycation end products (AGEs), and increased d-lactate, reflecting greater methylglyoxal flux." | 7.01 | Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub-study. ( Hanssen, NMJ; Hovind, P; Parving, HH; Persson, F; Piazza, M; Rossing, P; Schalkwijk, CG; Scheijen, JL; Stehouwer, CDA; van de Waarenburg, MPH; van Greevenbroek, MMJ, 2021) |
| "The aim of this study was to assess the effects of irbesartan alone and combined with amlodipine, efonidipine, or trichlormethiazide on blood pressure (BP) and urinary albumin (UA) excretion in hypertensive patients with microalbuminuria (30≤UA/creatinine (Cr) ratio [UACR] <300 mg/g Cr) and upper-normal microalbuminuria (10≤UACR<30 mg/g Cr)." | 5.27 | Effect of amlodipine, efonidipine, and trichlormethiazide on home blood pressure and upper-normal microalbuminuria assessed by casual spot urine test in essential hypertensive patients. ( Asayama, K; Hanazawa, T; Hosaka, M; Imai, Y; Inoue, R; Obara, T; Ohkubo, T; Satoh, M; Watabe, D, 2018) |
| "Changes in systolic blood pressure (SBP), albuminuria, potassium, haemoglobin, cholesterol and uric acid after 6 months of losartan treatment were assessed in the RENAAL database." | 5.20 | The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. ( de Zeeuw, D; Lambers Heerspink, HJ; Parving, HH; Rossing, P; Schievink, B, 2015) |
| "In a multi-center, single-arm, prospective study, we investigated the efficacy and safety of the fixed irbesartan/hydrochlorothiazide combination in Chinese patients with moderate to severe hypertension." | 5.17 | Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension. ( Dai, QY; Huang, QF; Li, Y; Ma, GS; Sheng, CS; Wang, JG, 2013) |
| " Therefore, we investigated the effects of irbesartan treatment on plasma levels of the AGEs N(ε)(1-carboxymethyl)lysine (CML) and N(ε)(1-carboxyethyl)lysine (CEL) in hypertensive patients with type 2 diabetes and microalbuminuria." | 5.15 | Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial. ( Engelen, L; Ferreira, I; Hovind, P; Parving, HH; Persson, F; Rossing, P; Schalkwijk, CG; Stehouwer, CD; Teerlink, T, 2011) |
| " After a 1-month washout period, 26 patients with type 2 diabetes, hypertension, and albuminuria (>100 mg/day) were randomly assigned to four 2-month treatment periods in random order with placebo, 300 mg aliskiren once daily, 300 mg irbesartan once daily, or the combination using identical doses." | 5.14 | Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. ( Boomsma, F; Danser, AH; Frandsen, E; Juhl, T; Parving, HH; Persson, F; Reinhard, H; Rossing, P; Schalkwijk, C; Stehouwer, CD, 2009) |
| " Inclusion criteria were type 2 diabetes, hypertension > 140/90 mmHg and current treatment with irbesartan or irbesartan/hydrochlorothiazide (HTCZ)." | 5.11 | [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ]. ( Krekler, M; Schmieder, RE, 2005) |
| " Risk factors for diabetic nephropathy are discussed, and include hyperglycemia, hypertension, angiotensin II, proteinuria, dyslipidemia, smoking, and anemia." | 4.82 | Outcome studies in diabetic nephropathy. ( Mohanram, A; Toto, RD, 2003) |
| "Currently, AIIAs such as losartan represent the only evidence-based treatment strategy for patients with type 2 DM and proteinuria." | 4.82 | Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. ( Ruilope, LM; Segura, J, 2003) |
| "The Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial demonstrated that adding aliskiren, an oral direct renin inhibitor, at a dosage of 300 mg/d to the highest approved dosage of losartan and optimal antihypertensive therapy reduces albuminuria over 6 mo among patients with type 2 diabetes, hypertension, and albuminuria." | 3.75 | Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. ( Charney, A; Delea, TE; Lau, H; Munk, VC; Palmer, JL; Parving, HH; Sofrygin, O; Sullivan, SD; Sung, J, 2009) |
| "Diabetic spontaneously hypertensive rats developed albuminuria and had a reduction in both gene and protein expression of nephrin when compared with control rats." | 3.71 | Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. ( Allen, TJ; Boner, G; Bonnet, F; Cao, Z; Cooper, ME; Kawachi, H, 2001) |
| "We investigated, in individuals with type 2 diabetes, whether irbesartan lowered plasma levels of the dicarbonyls methylglyoxal, glyoxal, 3-deoxyglucosone and their derived advanced glycation end products (AGEs), and increased d-lactate, reflecting greater methylglyoxal flux." | 3.01 | Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub-study. ( Hanssen, NMJ; Hovind, P; Parving, HH; Persson, F; Piazza, M; Rossing, P; Schalkwijk, CG; Scheijen, JL; Stehouwer, CDA; van de Waarenburg, MPH; van Greevenbroek, MMJ, 2021) |
| " Patients were randomly divided into 4 groups: low-dose irbesartan (group A), high-dose irbesartan (group B), low-dose irbesartan combined with spironolactone (group C) and high-dose irbesartan combined with spironolactone (group D)." | 2.87 | Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy. ( Chen, X; Chen, Y; Li, Y; Liu, P; Wang, Y; Zhang, F, 2018) |
| "Treatment of patients with type 2 diabetes with Irbesartan decreased urinary excretion of MG-H1, G-H1 and 3-NT, which may result from decreased exposure to these AGEs." | 2.77 | Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria. ( Adaikalakoteswari, A; Parving, HH; Rabbani, N; Rossing, K; Rossing, P; Tarnow, L; Thornalley, PJ, 2012) |
| "The Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) study was a 2-year multicenter randomized double-blind trial comparing irbesartan (150 and 300 mg once daily) with placebo." | 2.76 | Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy. ( Afzal, S; Andersen, JT; Broedbaek, K; Henriksen, T; Jimenez-Solem, E; Parving, HH; Persson, F; Petersen, M; Poulsen, HE; Rossing, P; Weimann, A, 2011) |
| "A total of 40 normotensive type 2 diabetes patients (mean age 55." | 2.73 | Short-term effects of irbesartan treatment on microalbuminuria in patients with normotensive type 2 diabetes. ( Cetinkalp, SS; Erdogan, MA; Karadeniz, MM; Ozgen, GA; Yilmaz, CO, 2008) |
| " The dosage was doubled if necessary." | 2.71 | Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood. ( Bianchetti, MG; Edefonti, A; Fossali, E; Gartenmann, AC; Schmidtko, J; Simonetti, GD; von Vigier, RO, 2003) |
| "Ultrahigh dosing of irbesartan (900 mg once daily) is generally safe and offers additional renoprotection independent of changes in systemic blood pressure and GFR in comparison to the currently recommended dose of 300 mg." | 2.71 | Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. ( Boomsma, F; Jensen, BR; Parving, HH; Rossing, K; Schjoedt, KJ, 2005) |
| "Patients with high blood pressure are often overweight or even obese." | 2.71 | [Arterial hypertension in obese patients. Rationale for a prospective medical care study in the family doctor's practice]. ( Bramlage, P; Kirch, W; Sharma, AM, 2004) |
| "Irbesartan treatment of patients with type 2 diabetes, hypertension, and microalbuminuria may lead to major improvements in long-term patient outcomes, with substantial cost savings as an added bonus to third party payers." | 2.42 | Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria. ( Palmer, AJ; Rodby, RA, 2004) |
| "Recently, the Reduction of Endpoints in NIDDM (non-insulin-dependent diabetes mellitus) with the Angiotensin II Antagonist Losartan (RENAAL) trial provided sufficient data to conclude that the blockade of the All AT1 receptor with losartan confers renoprotection in patients with DM-2 and nephropathy." | 2.41 | The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies. ( Ribeiro, AB; Zanella, MT, 2002) |
| "HKC was administered to the diabetic nephropathy rats at three different doses: high dose HKC (300mg/kg/d); middle dose HKC (175mg/kg/d); and low dose HKC (75mg/kg/d)." | 1.43 | Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, improves diabetic nephropathy via activating peroxisome proliferator-activated receptor (PPAR)-α/γ and attenuating endoplasmic reticulum stress in rats. ( Ge, J; Miao, JJ; Sun, XY; Yu, JY, 2016) |
| "Data from patients with type 2 diabetes and microalbuminuria (n = 49) treated with irbesartan 300 mg/day were used for discovery." | 1.43 | Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus. ( Andersen, S; Dallmann, G; Heerspink, HJ; Heinzel, A; Mayer, B; Parving, HH; Pena, MJ; Rossing, K; Rossing, P, 2016) |
| "Captopril treatment reduced blood pressure (163+/-3 mmHg versus diabetic 201+/-3 mmHg), but not albumin excretion rate (43." | 1.31 | Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. ( Allen, TJ; Bonnet, F; Cao, Z; Cooper, ME; Davis, B, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.35) | 18.2507 |
| 2000's | 50 (67.57) | 29.6817 |
| 2010's | 20 (27.03) | 24.3611 |
| 2020's | 3 (4.05) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, J | 1 |
| Tostivint, I | 1 |
| Xu, L | 1 |
| Huang, J | 1 |
| Gambotti, L | 1 |
| Boffa, JJ | 1 |
| Yang, M | 1 |
| Wang, L | 1 |
| Sun, Z | 1 |
| Chen, X | 2 |
| Liou-Schischmanoff, A | 1 |
| Baumelou, A | 1 |
| Ma, T | 1 |
| Lu, G | 1 |
| Li, L | 1 |
| Chen, D | 1 |
| Piéroni, L | 1 |
| Liu, B | 1 |
| Qin, X | 1 |
| He, W | 1 |
| Wang, Y | 2 |
| Gu, HF | 1 |
| Sun, W | 1 |
| Shin, J | 1 |
| Kim, HS | 1 |
| Min Kim, T | 1 |
| Kim, H | 1 |
| Lee, SH | 1 |
| Hyoung Cho, J | 1 |
| Lee, H | 1 |
| Woo Yim, H | 1 |
| Yoon, KH | 1 |
| Piazza, M | 1 |
| Hanssen, NMJ | 1 |
| Persson, F | 7 |
| Scheijen, JL | 1 |
| van de Waarenburg, MPH | 1 |
| van Greevenbroek, MMJ | 1 |
| Rossing, P | 11 |
| Hovind, P | 5 |
| Stehouwer, CDA | 1 |
| Parving, HH | 22 |
| Schalkwijk, CG | 3 |
| Hosaka, M | 1 |
| Inoue, R | 1 |
| Satoh, M | 2 |
| Watabe, D | 1 |
| Hanazawa, T | 1 |
| Ohkubo, T | 1 |
| Asayama, K | 1 |
| Obara, T | 1 |
| Imai, Y | 1 |
| Zhao, XM | 1 |
| Zhang, Y | 1 |
| He, XH | 1 |
| Chen, HD | 1 |
| Wang, ZF | 1 |
| Guo, J | 1 |
| Wang, XM | 1 |
| Gao, ZZ | 1 |
| Wang, JP | 1 |
| Liu, W | 1 |
| Zhao, LH | 1 |
| Tong, XL | 1 |
| Chen, Y | 1 |
| Liu, P | 1 |
| Li, Y | 2 |
| Zhang, F | 1 |
| Huang, QF | 1 |
| Sheng, CS | 1 |
| Ma, GS | 1 |
| Dai, QY | 1 |
| Wang, JG | 1 |
| Schievink, B | 1 |
| de Zeeuw, D | 6 |
| Lambers Heerspink, HJ | 3 |
| Hayashi, K | 2 |
| Sasamura, H | 1 |
| Nakamura, M | 1 |
| Sakamaki, Y | 1 |
| Azegami, T | 1 |
| Oguchi, H | 1 |
| Tokuyama, H | 1 |
| Wakino, S | 1 |
| Itoh, H | 1 |
| Felix Kröpelin, T | 1 |
| Holtkamp, FA | 2 |
| Packham, DK | 1 |
| L Heerspink, HJ | 1 |
| Ge, J | 1 |
| Miao, JJ | 1 |
| Sun, XY | 1 |
| Yu, JY | 1 |
| Pena, MJ | 1 |
| Heinzel, A | 1 |
| Dallmann, G | 1 |
| Rossing, K | 6 |
| Andersen, S | 8 |
| Mayer, B | 1 |
| Heerspink, HJ | 1 |
| Stehouwer, CD | 4 |
| Tarnow, L | 3 |
| Cetinkalp, SS | 1 |
| Karadeniz, MM | 1 |
| Erdogan, MA | 1 |
| Ozgen, GA | 1 |
| Yilmaz, CO | 1 |
| Reinhard, H | 1 |
| Juhl, T | 1 |
| Schalkwijk, C | 2 |
| Danser, AH | 1 |
| Boomsma, F | 2 |
| Frandsen, E | 1 |
| Delea, TE | 1 |
| Sofrygin, O | 1 |
| Palmer, JL | 1 |
| Lau, H | 1 |
| Munk, VC | 1 |
| Sung, J | 1 |
| Charney, A | 1 |
| Sullivan, SD | 1 |
| Whaley-Connell, A | 1 |
| Nistala, R | 1 |
| Habibi, J | 1 |
| Hayden, MR | 1 |
| Schneider, RI | 1 |
| Johnson, MS | 1 |
| Tilmon, R | 1 |
| Rehmer, N | 1 |
| Ferrario, CM | 1 |
| Sowers, JR | 1 |
| Kuwabara, A | 1 |
| Tomita, N | 1 |
| Sasaki, T | 1 |
| Kashihara, N | 1 |
| Mischak, H | 1 |
| Zürbig, P | 1 |
| Tebbe, U | 2 |
| Bramlage, P | 6 |
| Lüders, S | 2 |
| Cuneo, A | 1 |
| Sistig, P | 1 |
| de Haan, F | 2 |
| Schmieder, R | 1 |
| Böhm, M | 2 |
| Paar, WD | 3 |
| Schrader, J | 2 |
| Dai, HY | 1 |
| Zheng, M | 1 |
| Tang, RN | 1 |
| Ni, J | 1 |
| Ma, KL | 1 |
| Li, Q | 1 |
| Liu, BC | 1 |
| Rabbani, N | 1 |
| Adaikalakoteswari, A | 1 |
| Thornalley, PJ | 1 |
| Engelen, L | 1 |
| Ferreira, I | 1 |
| Teerlink, T | 1 |
| de Graeff, PA | 1 |
| Laverman, GD | 1 |
| Berl, T | 1 |
| Remuzzi, G | 1 |
| Packham, D | 1 |
| Lewis, JB | 1 |
| Broedbaek, K | 1 |
| Henriksen, T | 1 |
| Weimann, A | 1 |
| Petersen, M | 1 |
| Andersen, JT | 1 |
| Afzal, S | 1 |
| Jimenez-Solem, E | 1 |
| Poulsen, HE | 1 |
| Nakamura, T | 1 |
| Kataoka, K | 1 |
| Tokutomi, Y | 1 |
| Nako, H | 1 |
| Toyama, K | 1 |
| Dong, YF | 1 |
| Koibuchi, N | 1 |
| Yamamoto, E | 1 |
| Yasuda, O | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Hellemons, ME | 1 |
| Bakker, SJ | 1 |
| Zanella, MT | 1 |
| Ribeiro, AB | 1 |
| Eguchi, K | 1 |
| Kario, K | 1 |
| Shimada, K | 1 |
| Sasso, FC | 1 |
| Carbonara, O | 1 |
| Persico, M | 1 |
| Iafusco, D | 1 |
| Salvatore, T | 1 |
| D'Ambrosio, R | 1 |
| Torella, R | 1 |
| Cozzolino, D | 1 |
| Haneda, M | 1 |
| Christensen, PK | 1 |
| Hansen, HP | 1 |
| Jacobsen, P | 2 |
| Jensen, BR | 2 |
| Mohanram, A | 1 |
| Toto, RD | 1 |
| Gartenmann, AC | 1 |
| Fossali, E | 1 |
| von Vigier, RO | 1 |
| Simonetti, GD | 1 |
| Schmidtko, J | 1 |
| Edefonti, A | 1 |
| Bianchetti, MG | 1 |
| González-Albarrán, O | 1 |
| Gómez, O | 1 |
| Ruiz, E | 1 |
| Vieitez, P | 1 |
| García-Robles, R | 1 |
| Bröchner-Mortensen, J | 2 |
| Lehnert, H | 4 |
| Pittrow, D | 2 |
| Kirch, W | 3 |
| Ruilope, LM | 1 |
| Segura, J | 1 |
| Kaiser, T | 1 |
| Florack, C | 1 |
| Sawicki, PT | 1 |
| Schunkert, H | 1 |
| Palmer, AJ | 5 |
| Rodby, RA | 3 |
| Llewelyn, DE | 1 |
| Garcia-Puig, J | 1 |
| de Alvaro, F | 2 |
| Velasco, O | 1 |
| Honorato, J | 1 |
| Calvo, C | 1 |
| Parrondo, I | 1 |
| Annemans, L | 2 |
| Roze, S | 4 |
| Lapuerta, P | 2 |
| Chen, R | 2 |
| Gabriel, S | 2 |
| Carita, P | 2 |
| Chiarelli, F | 1 |
| Di Marzio, D | 1 |
| Santilli, F | 1 |
| Mohn, A | 1 |
| Blasetti, A | 1 |
| Cipollone, F | 1 |
| Mezzetti, A | 1 |
| Verrotti, A | 1 |
| Schjoedt, KJ | 1 |
| Schmieder, RE | 3 |
| Krekler, M | 2 |
| Sharma, AM | 1 |
| Valentine, WJ | 3 |
| Ray, JA | 3 |
| Frei, A | 1 |
| Burnier, M | 1 |
| Hess, B | 1 |
| Spinas, GA | 1 |
| Brändle, M | 1 |
| Tschöpe, C | 1 |
| Tschöpe, R | 1 |
| Unger, T | 1 |
| Tucker, DM | 1 |
| Laville, M | 1 |
| Muszbek, N | 1 |
| Wong, DW | 1 |
| Oudit, GY | 1 |
| Reich, H | 1 |
| Kassiri, Z | 1 |
| Zhou, J | 1 |
| Liu, QC | 1 |
| Backx, PH | 1 |
| Penninger, JM | 1 |
| Herzenberg, AM | 1 |
| Scholey, JW | 1 |
| Bakris, GL | 1 |
| Ruilope, L | 1 |
| Locatelli, F | 1 |
| Ptaszynska, A | 1 |
| Pieske, B | 1 |
| de Champlain, J | 1 |
| Weber, MA | 1 |
| Raz, I | 1 |
| Tuttle, KR | 1 |
| Flack, JM | 1 |
| Thoenes, M | 2 |
| Bramlage, CP | 1 |
| O'Donnell, MP | 1 |
| Crary, GS | 1 |
| Oda, H | 1 |
| Kasiske, BL | 1 |
| Powell, JR | 1 |
| Keane, WF | 1 |
| Cao, Z | 2 |
| Bonnet, F | 2 |
| Davis, B | 1 |
| Allen, TJ | 2 |
| Cooper, ME | 2 |
| Kawachi, H | 1 |
| Boner, G | 1 |
| Gomis, R | 2 |
| Arner, P | 2 |
| Bloomgarden, ZT | 1 |
| Brøchner-Mortensen, J | 1 |
| Hansen, BV | 1 |
| Studney, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Parallel-controlled, Multi-center Clinical Trial of HuangKui Capsule to Treat Diabetic Kidney Disease[NCT03016832] | Early Phase 1 | 414 participants (Anticipated) | Interventional | 2017-01-31 | Recruiting | ||
| The Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2)[NCT00317915] | Phase 3 | 0 participants | Interventional | Completed | |||
| A Randomized, Double-Blind, Parallel-Group, Cross-Over, 4-Period, 4 Treatment, Within-Subject Placebo-Controlled Study to Assess the Reno-Protective Effect of Renin Inhibition With Aliskiren as an Alternative to Irbesartan in Type 2 Patients With Incipien[NCT00464880] | Phase 1/Phase 2 | 24 participants | Interventional | 2005-09-30 | Completed | ||
| Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria[NCT00320879] | Phase 4 | 52 participants | Interventional | 2003-09-30 | Completed | ||
| Pre-existing Microalbuminuria Predicting Contrast-induced Acute Kidney Injury (CIAKI) Following Coronary Angiography (CAG)[NCT02808845] | 800 participants (Anticipated) | Observational | 2016-12-31 | Not yet recruiting | |||
| Irbesartan Versus Placebo in Combination With Standard Cardiovascular Protection ACE-I Therapy With Ramipril for the Treatment of Albuminuria in Hypertensive Subjects at Elevated Cardiovascular Risk[NCT00095290] | Phase 4 | 400 participants | Interventional | 2004-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for avapro and Albuminuria
| Article | Year |
|---|---|
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; | 2011 |
The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2002 |
[What is a good marker for better antihypertensive therapy in diabetic patients when coexisting with hypertension].
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; | 2002 |
[Diabetic nephropathy].
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biomarkers; | 2002 |
Outcome studies in diabetic nephropathy.
Topics: Albuminuria; Anemia; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme | 2003 |
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
Topics: Albuminuria; Amlodipine; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Clinical Trial | 2003 |
Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria.
Topics: Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Cost Savings; Diabetes Mellitus, Type 2; H | 2004 |
Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan/hydrochlorothiazide.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; D | 2007 |
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2002 |
31 trials available for avapro and Albuminuria
| Article | Year |
|---|---|
Efficacy of Combined Abelmoschus manihot and Irbesartan for Reduction of Albuminuria in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter Randomized Double-Blind Parallel Controlled Clinical Trial.
Topics: Abelmoschus; Albuminuria; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dou | 2022 |
Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub-study.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Chromatography, Liquid; Deoxygluco | 2021 |
Effect of amlodipine, efonidipine, and trichlormethiazide on home blood pressure and upper-normal microalbuminuria assessed by casual spot urine test in essential hypertensive patients.
Topics: Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Blood Pr | 2018 |
Chinese herbal medicine Shenzhuo Formula treatment in patients with macroalbuminuria secondary to diabetic kidney disease: study protocol for a randomized controlled trial.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Biomarkers; China; Creatinine; Diabetic Nephro | 2018 |
Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Diabetic Neph | 2018 |
Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension.
Topics: Adolescent; Adult; Aged; Albuminuria; Antihypertensive Agents; Asian People; Biphenyl Compounds; Blo | 2013 |
The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Blood Pr | 2015 |
Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study.
Topics: Adult; Aged; Albuminuria; Biomarkers; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephro | 2008 |
Short-term effects of irbesartan treatment on microalbuminuria in patients with normotensive type 2 diabetes.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pressure; Diabetes M | 2008 |
Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amides; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; D | 2009 |
Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria.
Topics: Albuminuria; Amino Acids; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Bendrofl | 2012 |
Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Diabetes | 2011 |
Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy.
Topics: Aged; Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Double-Bl | 2011 |
initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; Diab | 2011 |
Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study.
Topics: Adult; Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Cross-Over Studies; Diabetes Mellit | 2002 |
Comparative effects of Irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Blood Pressur | 2003 |
Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Comp | 2003 |
Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood.
Topics: Adolescent; Albuminuria; Amlodipine; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Bl | 2003 |
Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria.
Topics: Albuminuria; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diabetes M | 2003 |
[IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].
Topics: Adolescent; Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agen | 2003 |
How different urinary albumin excretion rates can predict progression to nephropathy and the effect of treatment in hypertensive diabetics.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Diabetic Angiopathies; Diabet | 2004 |
Microalbuminuria in hypertensive patients: evaluation of one-year treatment with irbesartan.
Topics: Albuminuria; Algorithms; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Female; Follow | 2005 |
Effects of irbesartan on intracellular antioxidant enzyme expression and activity in adolescents and young adults with early diabetic angiopathy.
Topics: Adolescent; Adult; Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Case-Co | 2005 |
Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood P | 2005 |
[Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ].
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compou | 2005 |
[Arterial hypertension in obese patients. Rationale for a prospective medical care study in the family doctor's practice].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; C | 2004 |
Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy.
Topics: Aged; Albuminuria; Antihypertensive Agents; Biomarkers; Biphenyl Compounds; Diabetes Mellitus, Type | 2006 |
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial.
Topics: Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convertin | 2007 |
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial.
Topics: Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convertin | 2007 |
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial.
Topics: Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convertin | 2007 |
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial.
Topics: Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convertin | 2007 |
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compou | 2001 |
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Topics: Adult; Aged; Albuminuria; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Cardiovascula | 2001 |
Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; | 2002 |
34 other studies available for avapro and Albuminuria
| Article | Year |
|---|---|
The short-term effects of angiotensin II receptor blockers on albuminuria and renal function in Korean patients.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazo | 2020 |
Renin-angiotensin blockade resets podocyte epigenome through Kruppel-like Factor 4 and attenuates proteinuria.
Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphe | 2015 |
Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome.
Topics: Adult; Aged; Albuminuria; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus, T | 2016 |
Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, improves diabetic nephropathy via activating peroxisome proliferator-activated receptor (PPAR)-α/γ and attenuating endoplasmic reticulum stress in rats.
Topics: Abelmoschus; Administration, Oral; Albuminuria; Animals; Biphenyl Compounds; Capsules; Diabetes Mell | 2016 |
Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus.
Topics: Adult; Albuminuria; Angiotensin Receptor Antagonists; Biphenyl Compounds; Diabetes Mellitus, Type 2; | 2016 |
Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria.
Topics: Albuminuria; Amides; Biphenyl Compounds; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic | 2009 |
Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat.
Topics: Albuminuria; Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Comp | 2010 |
Deterioration of glomerular endothelial surface layer induced by oxidative stress is implicated in altered permeability of macromolecules in Zucker fatty rats.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blotting, Western | 2010 |
Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Diabetes Mellitus, Type 2; | 2010 |
Follow-up of cardiovascular risk markers in hypertensive patients treated with irbesartan: results of the i-SEARCH Plus Registry.
Topics: Aged; Albuminuria; Antihypertensive Agents; Biomarkers; Biphenyl Compounds; C-Reactive Protein; Card | 2010 |
Effects of angiotensin receptor blocker on phenotypic alterations of podocytes in early diabetic nephropathy.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; | 2011 |
Novel mechanism of salt-induced glomerular injury: critical role of eNOS and angiotensin II.
Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Bipheny | 2011 |
[Dangerous deficits in management of hypertensive diabetic patients. A kidney check is far from standard procedure].
Topics: Albuminuria; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes | 2003 |
Role of systolic blood pressureon the progression of kidney damage in an experimental model of type 2 diabetes mellitus, obesity, and hypertension (Zucker rats).
Topics: Albuminuria; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus | 2003 |
[Prospective treatment study of irbesartan. Diabetic kidneys regain function].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; C | 2003 |
[Diabetic patients have to be tested regularly for microalbuminuria. Almost every second one has already kidney damage].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; C | 2004 |
Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria: response to Andersen, Brochner-Mortensen, and Parving.
Topics: Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephro | 2004 |
[A threat to cardiovascular risk patients. "Activated renin-angiotensin system promotes end organ damage" (interview by Waldtraud Paukstadt)].
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Diseases; | 2004 |
[Test for microalbuminuria. Life saving for hypertensive and diabetic patients].
Topics: Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Coronary Artery Disease; Diabetic Nephropa | 2004 |
Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria.
Topics: Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cost Savings; Diabetes Mel | 2005 |
[Observational study of blood pressure control and microalbuminuria in type 2 diabetics on Irbesartan or Irbesartan/HCTZ].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; C | 2005 |
Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; C | 2006 |
[Microalbuminuria in patients with hypertension and cardiovascular comorbidity, REAL observational study of treatment with Irbesartan/HCTZ].
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compo | 2006 |
A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cost-Benefit Analysis; Dia | 2006 |
Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis.
Topics: Albuminuria; Antihypertensive Agents; Biphenyl Compounds; Cohort Studies; Comorbidity; Costs and Cos | 2007 |
Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury.
Topics: Actins; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Anima | 2007 |
Albuminuria reduction: the holy grail for kidney protection.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biom | 2007 |
[Long-term follow-up of cardiovascular risk markers in patients with hypertension. Rationale, design, and baseline characteristics of the i-Search Plus Registry].
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl | 2007 |
[Albuminuria: an indicator of cardiovascular risk].
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Antihypertensi | 2007 |
Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biphenyl Co | 1997 |
Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats.
Topics: Albuminuria; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2001 |
Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension.
Topics: Albuminuria; Analysis of Variance; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Di | 2001 |
Angiotensin II receptor blockers and nephropathy trials.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; | 2001 |
[Diabetic patient with hypertension takes A-I I blocker. Less likely dialysis].
Topics: Albuminuria; Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2002 |